UP!

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2015 2016-02-23 Future report Set alerts
Q2 2015 2015-11-19 Future report Set alerts
Q1 2015 2015-08-20 0.72 0.47
Q4 2014 2015-06-04 0.64 0.40
Q3 2014 2015-02-26 0.59 0.62
Q2 2014 2014-11-20 0.63 0.64
Q1 2014 2014-08-21 0.53 0.50
Q4 2013 2014-06-04 0.55 0.68
Q3 2013 2014-02-20 0.51 0.51
Q2 2013 2013-11-21 0.50 0.50

Ratings

2015-08-21 Reiterated Rating Jefferies Group Hold $58.00 to $60.00
2015-08-21 Reiterated Rating Canaccord Genuity Hold $65.00 to $67.00
2015-08-20 Reiterated Rating William Blair Outperform
2015-08-20 Reiterated Rating BTIG Research Neutral
2015-07-27 Reiterated Rating Canaccord Genuity Hold $65.00
2015-06-05 Reiterated Rating Canaccord Genuity Hold $62.00 to $65.00
2015-06-05 Lower Price Target Jefferies Group Hold $75.00 to $58.00
2015-06-05 Reiterated Rating BTIG Research Neutral
2015-03-06 Downgrade Jefferies Group Buy to Hold $83.00 to $75.00
2015-02-27 Boost Price Target Jefferies Group Buy $70.00 to $83.00
2015-02-27 Reiterated Rating BTIG Research Neutral
2015-02-27 Boost Price Target Canaccord Genuity Hold $52.00 to $62.00
2015-02-26 Downgrade Sidoti Buy to Neutral
2014-11-21 Downgrade Sterne Agee CRT Buy to Neutral
2014-08-22 Reiterated Rating Citigroup Inc. Buy $70.00 to $67.00
2014-08-22 Downgrade Canaccord Genuity Buy to Hold $63.00 to $52.00
2014-06-24 Initiated Coverage Sterne Agee CRT In-Line to Buy $65.00
2014-06-10 Reiterated Rating Jefferies Group Buy $80.00 to $70.00
2014-06-05 Lower Price Target Canaccord Genuity Buy $73.00 to $63.00
2014-06-05 Reiterated Rating Citigroup Inc. Buy $85.00 to $70.00
2014-04-24 Initiated Coverage BTIG Research Neutral
2014-02-21 Reiterated Rating Citigroup Inc. Buy $80.00 to $85.00
2013-12-06 Reiterated Rating Citigroup Inc. Buy $71.00 to $80.00
2013-12-06 Boost Price Target Canaccord Genuity Buy $70.00 to $73.00
2013-11-22 Boost Price Target Jefferies Group $60.00 to $80.00
2013-11-22 Boost Price Target Canaccord Genuity Buy $57.00 to $70.00
2013-11-18 Initiated Coverage Citigroup Inc. Buy $71.00
2013-06-06 Upgrade Northland Capital Under Perform to Market Perform $40 to $44
2012-09-26 Reiterated WBB Securities Strong Buy $60
2012-08-09 Initiated William Blair Outperform
2012-01-03 Upgrade Kaufman Bros Hold to Buy $28 to $38
2011-06-03 Upgrade WBB Securities Buy to Strong Buy
2011-06-03 Reiterated Canaccord Genuity Hold $30.50 to $26.50
2011-01-31 Reiterated WBB Securities Buy $22 to $38
2011-01-04 Initiated Jefferies Buy $37
2010-07-20 Initiated Dougherty & Company Buy $29
2010-02-19 Downgrade WBB Securities Strong Buy to Buy $17.50 to $22
2009-12-01 Initiated Robert W. Baird Neutral $17
2015-08-21 Reiterated Rating Jefferies Group Hold $58.00 to $60.00
2015-08-21 Reiterated Rating Canaccord Genuity Hold $65.00 to $67.00
2015-08-20 Reiterated Rating William Blair Outperform
2015-08-20 Reiterated Rating BTIG Research Neutral
2015-07-27 Reiterated Rating Canaccord Genuity Hold $65.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Verratti Mark VP Global Sales 0.21%  (54663) CYBX / MYGN /
Olin Bryan D VP Clinical Quality Regulatory 0.20%  (53424) CYBX /
SIMPSON RANDAL L VP Operations 0.16%  (43669) CYBX /
KenKnight Bruce H VP, Emerging Therapies 0.14%  (38519) CYBX /
ROSENTHAL ARTHUR L 0.12%  (31076) CYBX /
Perkins Sherrie L VP, Mktg & NBD 0.09%  (24161) CYBX /
Morris Milton Mayo SR VP Research & Development 0.08%  (21146) CYBX /

Comments